Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023
- Sight Sciences will be hosting a TearCare SAHARA Six Month RCT Results reception in San Francisco on November 3, 2023.
- The event will include a presentation on the successful six month results of the SAHARA head-to-head clinical trial comparing TearCare to Restasis for the treatment of dry eye disease.
- A live and archived webcast of the event will be available on Sight Sciences' investor relations website.
- None.
The event will include a presentation from Brandon Ayres, MD, Wills Eye Hospital and Sight Sciences executive management team on the successful six month results of the SAHARA head-to head randomized controlled clinical trial comparing TearCare® to Restasis® for the treatment of dry eye disease
MENLO PARK, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced they will be hosting a TearCare SAHARA Six Month RCT Results reception in San Francisco, CA on Friday, November 3, 2023 from 5:00 to 7:00 pm PT.
A live and archived webcast of the event will be available on Sight Sciences’ investor relations website at https://investors.sightsciences.com. Please note that Q&A will be conducted live, in-person only following the formal presentation.
In-person attendance at the event will be limited and require advanced registration. Please email Hannah@gilmartinir.com by October 30, 2023 to request an invitation.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (“MIGS”) technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (“POAG”), the world’s leading cause of irreversible blindness. The Company’s TearCare System technology is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”) when used in conjunction with manual expression of the meibomian glands, enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
For more information, visit www.sightsciences.com.
OMNI and TearCare are registered trademarks of Sight Sciences.
SION is a trademark of Sight Sciences.
Restasis is a registered trademark of Allergan, an AbbVie company.
© 2023 Sight Sciences. All rights reserved.
Media contact
pr@SightSciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
What is the purpose of the TearCare SAHARA Six Month RCT Results reception?
When and where will the reception take place?
Will there be a webcast of the event?
How can I request an invitation to attend the event?
